Equities

Keros Therapeutics Inc

KROS:NMQ

Keros Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)49.36
  • Today's Change-0.14 / -0.28%
  • Shares traded280.35k
  • 1 Year change+27.91%
  • Beta1.2491
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

  • Revenue in USD (TTM)234.00k
  • Net income in USD-160.30m
  • Incorporated2015
  • Employees141.00
  • Location
    Keros Therapeutics Inc1050 Waltham Street, Suite 302LEXINGTON 02421United StatesUSA
  • Phone+1 (617) 314-6297
  • Websitehttps://www.kerostx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Taro Pharmaceutical Industries Ltd629.18m53.87m1.61bn1.55k29.810.895818.902.551.431.4316.7447.700.29281.503.31--2.51-0.1663.03-0.202348.4752.858.56-0.62943.04--0.00--9.81-1.25111.70-28.1712.06--
Edgewise Therapeutics Inc0.00-105.85m1.64bn92.00--3.05-----1.53-1.530.005.730.00----0.00-23.52---24.25--------------0.00-------48.08------
Harmony Biosciences Holdings Inc617.51m137.70m1.65bn246.0012.543.2010.182.672.322.3210.399.080.790625.729.342,510,207.0017.637.4620.839.0879.2880.5822.3010.463.0731.380.26940.0032.93---28.99---25.31--
Akero Therapeutics Inc0.00-179.27m1.66bn58.00--1.96-----3.20-3.200.0012.240.00----0.00-28.43-37.73-29.53-40.13------------0.0395-------35.46------
Syndax Pharmaceuticals Inc0.00-240.63m1.71bn112.00--3.47-----3.22-3.220.005.790.00----0.00-47.99-27.90-51.84-30.15-------324.34----0.00004-------40.19------
Arvinas Inc71.30m-354.80m1.76bn445.00--2.88--24.64-6.05-6.051.228.930.0597--12.08160,224.70-29.59-22.01-37.90-26.47-----495.65-316.55----0.0012---40.2640.53-30.02--0.4852--
Catalyst Pharmaceuticals Inc411.35m65.12m1.78bn167.0027.973.1717.644.320.53840.53843.604.760.78063.608.762,463,156.0012.3625.4214.1929.8186.7485.6315.8330.874.83--0.000.0085.90280.39-14.05--20.21--
Keros Therapeutics Inc234.00k-160.30m1.78bn141.00--3.92--7,611.54-5.14-5.140.007512.590.0005----1,720.59-36.84-35.95-38.35-38.07-----68,505.13-1,237.26----0.00-----56.77-46.15--62.57--
Maravai Lifesciences Holdings Inc274.10m-131.04m1.89bn570.00--4.61--6.91-0.9917-0.99172.081.630.14582.935.90421,690.80-8.4912.67-11.2915.4644.0374.79-58.2737.3210.47-2.020.41690.00-67.2818.47-154.05--78.56--
Immunocore Holdings PLC - ADR265.83m-59.44m1.92bn497.00--5.32--7.24-1.20-1.205.277.230.34860.4065.60534,860.40-7.80-27.55-9.40-36.8299.60---22.36-97.125.94--0.5489--43.0551.23-5.22--2.85--
Protagonist Therapeutics Inc314.95m162.11m1.96bn124.0013.583.4912.016.222.462.465.259.560.7248--2.102,812,080.0037.30-35.9040.23-41.36----51.47-332.81----0.00--125.7314.1738.02--4.62--
Data as of Jun 14 2024. Currency figures normalised to Keros Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

44.39%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 20244.36m12.09%
BlackRock Fund Advisorsas of 31 Mar 20241.87m5.17%
Alkeon Capital Management LLCas of 31 Mar 20241.60m4.43%
SSgA Funds Management, Inc.as of 31 Mar 20241.56m4.33%
The Vanguard Group, Inc.as of 31 Mar 20241.47m4.09%
Darwin Global Management Ltd.as of 31 Mar 20241.44m3.98%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20241.20m3.33%
Point72 Asset Management LPas of 31 Mar 2024971.88k2.69%
Silverbay Capital Management LLCas of 31 Mar 2024784.10k2.17%
Woodline Partners LPas of 31 Mar 2024761.70k2.11%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.